Interestingly, a protective effect of ML-SA1 has been demonstrated against α-synuclein toxicity in human dopaminergic neurons (Tsunemi et al., 2019), L-BMAA-induced neurodegeneration, modelling ALS, in primary neurons and in FIG4 deficiency linked to Charcot–Marie–Tooth disease (Edgar et al., 2020; Zou et al., 2015). Here, STAG1 is linked to amyotrophic lateral sclerosis.